Apnimed Inc. (APMD:NASDAQ) closed at $18.99 on October 23, 2026, up 2.48% on the day. The stock trades 46.2% below its 52-week high of $35.29 and 17.8% above its 52-week low of $16.12. Over the past year, it lost 24.0%. Apnimed Inc. is part of the Health Care sector.
In 59 trading sessions since August 3, 2026, APMD closed higher on 30 days (51%). Its best day was October 20, 2026 (+11.54%) and its worst was October 6, 2026 (-14.25%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.
Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with obstructive sleep apnea (OSA). We believe that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA's disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment and help more people get the oxygen and restorative sleep needed to thrive.
Find more stocks like APMD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.